OrbiMed’s Burning Rock Biotech BNR Stock Holding History

OrbiMed’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-128,282	Closed	-$3.07K	–	118
2022 Q3	$3.07K	Sell	128,282 -10,698	-8%	-$345K	0.06%	115
2022 Q2	$4.04K	Sell	138,980 -6,260	-4%	-$280K	0.07%	116
2022 Q1	$13.5M	Hold	145,240	–	–	0.22%	88
2021 Q4	$13.8M	Sell	145,240 -40,380	-22%	-$5.53M	0.18%	105
2021 Q3	$33.2M	Hold	185,620	–	–	0.36%	72
2021 Q2	$54.7M	Sell	185,620 -4,146	-2%	-$1.23M	0.55%	55
2021 Q1	$51.1M	Sell	189,766 -226,402	-54%	-$68.9M	0.48%	57
2020 Q4	$96.1M	Sell	416,168 -58,440	-12%	-$15.7M	0.84%	34
2020 Q3	$119M	Buy	474,608 +1	+0%	+$237	1.5%	19
2020 Q2	$128M	Buy	+474,607	New	+$130M	1.8%	20

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

OrbiMed's BNR Position: Q4 2022 in Review

OrbiMed sold out of Burning Rock Biotech (BNR) in Q4 2022, closing a stake of 128,282 shares — an estimated $3.07K sold.

OrbiMed first reported a position in BNR in Q2 2020 and held it in 10 quarters. The position peaked at $128M in Q2 2020. 42 funds tracked by Wall St. Rank hold BNR as of Q4 2022.

OrbiMed reported no remaining Burning Rock Biotech position as of Q4 2022 after selling out during the quarter.
OrbiMed sold 128,282 Burning Rock Biotech shares in Q4 2022, an estimated $3.07K.
OrbiMed first reported a position in Burning Rock Biotech in Q2 2020 and held it in 10 quarters.
OrbiMed's Burning Rock Biotech position peaked at $128M in Q2 2020.
42 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.